<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972396</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-801-103</org_study_id>
    <nct_id>NCT04972396</nct_id>
  </id_info>
  <brief_title>ALT-801 DDI Study in Healthy Volunteers</brief_title>
  <official_title>An Open-label Study of the Effect of ALT-801 on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin, Digoxin, and the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, drug-drug interaction (DDI) study of ALT-801 under steady&#xD;
      state conditions on concomitantly administered medications in healthy subjects. The study&#xD;
      will evaluate the effect of ALT-801 on the pharmacokinetics (PK) of metformin, warfarin,&#xD;
      atorvastatin, digoxin, and the combined oral contraceptive (OC)&#xD;
      ethinylestradiol/levonorgestrel. The study will be conducted in 3 parts, as described below.&#xD;
      Each part will have 2 periods in a fixed sequence, where the first period is without ALT-801&#xD;
      administration and the second is with ALT-801 at steady state.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of metformin and atorvastatin/warfarin and digoxin in presence of steady state ALT-801</measure>
    <time_frame>Baseline and Day 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of ethinylestradiol and levonorgestrel in presence of steady state ALT-801</measure>
    <time_frame>Baseline and Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax and Tmax of metformin and atorvastatin/warfarin and digoxin</measure>
    <time_frame>Day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax and Tmax of ethinylestradiol and levonorgestrel</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 77</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-801</intervention_name>
    <description>Injected subcutaneously (SC)</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Taken by mouth (PO)</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Taken by mouth (PO)</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Taken by mouth (PO)</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Taken by mouth (PO)</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinylestradiol and Levonorgestrel</intervention_name>
    <description>Taken by mouth (PO)</description>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female healthy volunteers, age 18 to 55 years, inclusive&#xD;
&#xD;
          -  Body mass index (BMI) 25.0- 40.0 kg/m2&#xD;
&#xD;
          -  Able and willing to provide written informed consent prior to entry into the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  History of diabetes or use of medications for the treatment of diabetes, or&#xD;
             hyperglycemia or HbA1c â‰¥ 6.5%&#xD;
&#xD;
          -  History of pancreatitis or hypersensitivity reaction to GLP-1 analogues&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Altimmune CTM</last_name>
    <phone>2406541450</phone>
    <email>information@altimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Q-Pharm</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CMAX Clinical Research</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

